From the laboratory to trials to routine use of phage in treating human infections
14.00 BST
Professor of Microbiology at the University of Leicester with experience in developing bacteriophage products
Clinical lecturer specialising in developing phages for clinical use
Can phages help address the challenges of AMR?
14.15 BST
Dr. Marie Noelle Vieu, MD
Public health consultant with experience in infectious disease management and health care needs analysis
Challenges of AMR; a clinical perspective and the acceptability of new alternatives
14.35 BST
David Jenkins
Dr David Jenkins is a renowned medical microbiologist and infection prevention specialist and President of BSAC. David has served as lead infection prevention clinician at University Hospital Leicester for over 20 years.
Phage therapy for compassionate use - lessons learned for clinical trials
15.25 BST
Microbiologist with a wealth of experience in researching phages for multidrug-resistant pathogens, currently leading the laboratory research component of the project
Immune response to phage and phage pharmacokinetics
15.40 BST
Krystyna Dabrowska
Professor of Molecular Microbiology at the Hirszfeld Institute of Immunology and Experimental Therapy in Wrocław, Poland, with experience in immune responses to phage, phage pharmacokinetics, and antibacterial potential of phages in vivo.
Phage clinical trials: not a novelty. What can the UK learn from other countries?
16.00 BST
Shawna McCallin
Dr. Shawna McCallin is a clinical trial coordinator and senior phage researcher at the Balgrist University Hospital at the University of Zürich, Switzerland.
Phage regulations and treatments; Belgium perspective
17.00 BST
Jean-Paul Pirnay
Dr. Jean-Paul Pirnay is head of the Laboratory for Molecular and Cellular Technology (LabMCT) and Research Manager of the Queen Astrid Military Hospital, where he contributed to the development of the human cell and tissue banks and to the re-introduction of phage therapy.
Phage regulation panel discussion
17.20 BST
Professor of Microbiology at the University of Leicester with experience in developing bacteriophage products
Should phage therapy be part of AMR strategy? What are the next steps?
17.40 BST
Professor of Microbiology at the University of Leicester with experience in developing bacteriophage products
Clinical lecturer specialising in developing phages for clinical use
Questions & reflections from the audience
14.55 BST
Professor of Microbiology at the University of Leicester with experience in developing bacteriophage products
Clinical trials of phage therapy in the UK: Making it a reality
16.30 BST
Panel discussion led by Prof. Martha Clokie
Professor of Microbiology at the University of Leicester with experience in developing bacteriophage products